Citi analyst Geoff Meacham maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $295.00. The company’s ...

Piper Sandler raised the firm’s price target on Amgen (AMGN) to $329 from $310 and keeps an Overweight rating on the shares. The firm notes the ...

Elsewhere, cell therapy developer Turnstone Biologics announced a second round of layoffs and plans to explore “strategic alternatives.” ...

Less than a decade since it secured its first FDA approval for a biosimilar, Amgen’s portfolio of the copycat drugs is growing and making strong contributions to the company’s top line.

Free cash flow surged to $4.4 billion, up a remarkable 1,367% year over year. Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Biotechnology specialist Amgen (NASDAQ:AMGN) reported fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 4, that topped analysts' consensus estimates. Analysts estimated Q4 adjusted EPS ...

Amgen is a biotechnology leader with competitive advantages in scale, R&D, manufacturing efficiency, and distribution, bolstered by a robust pipeline and rising margins. I currently rate Amgen as ...

Amgen, Inc. ( NASDAQ: AMGN) Oppenheimer 35th Annual Healthcare Life Sciences Conference Call February 12, 2025 11:20 AM ET Narimon Honarpour - Senior Vice President, Global Development Justin Claeys - ...

All of a sudden, Amgen stock is up 15% since late December to around $299. Its rise helped push up the healthcare sector up just over 7% since hitting a bottom in late December. The better-than ...

My name is Julianne, and I will be your conference facilitator today for Amgen's fourth quarter and full year 2024 financial results conference call. All lines have been placed on mute to prevent ...

(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation ...